Primary Aldosteronism and Ischemic Heart Disease

被引:2
|
作者
Patil, Shivaraj [1 ]
Rojulpote, Chaitanya [2 ]
Amanullah, Aman [1 ]
机构
[1] Einstein Med Ctr, Dept Cardiol, Philadelphia, PA 19141 USA
[2] Wright Ctr Grad Med Educ, Dept Med, Scranton, PA USA
来源
关键词
primary hyperaldosteronism (PA); ischemic heart disease; atherosclerosis; secondary hypertension; coronary artery disease; ELEVATION MYOCARDIAL-INFARCTION; TREATED PRIMARY ALDOSTERONISM; LEFT-VENTRICULAR DYSFUNCTION; COLLEGE-OF-CARDIOLOGY; CARDIOVASCULAR COMPLICATIONS; METABOLIC SYNDROME; SERUM ALDOSTERONE; RISK-FACTORS; HYPERTENSION; ASSOCIATION;
D O I
10.3389/fcvm.2022.882330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease, in particular ischemic heart disease is a major cause of morbidity and mortality worldwide. Primary aldosteronism is the leading cause of secondary hypertension, yet commonly under diagnosed, and represents a major preventable risk factor. In contrast to historical teaching, recent studies have shown that excess aldosterone production is associated with increased burden of ischemic heart disease disproportionate to the effects caused by hypertension alone. Aldosterone through its genomic and non-genomic actions exerts various detrimental cardiovascular changes contributing to this elevated risk. Recognition of primary hyperaldosteronism and understanding the distinctive pathophysiology of ischemic heart disease in primary aldosteronism is crucial to develop strategies to improve outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Detecting and treating primary aldosteronism - Primary aldosteronism
    Mantero, F.
    Mattarello, M. J.
    Albiger, N. M. E.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (03) : 171 - 174
  • [32] Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease
    Nakano, Yujiro
    Murakami, Masanori
    Hara, Kazunari
    Fukuda, Tatsuya
    Horino, Masato
    Takeuchi, Akira
    Niitsu, Yoshihiro
    Shiba, Kumiko
    Tsujimoto, Kazutaka
    Komiya, Chikara
    Yokoyama, Minato
    Ikeda, Kenji
    Yoshimoto, Takanobu
    Fujii, Yasuhisa
    Yamada, Tetsuya
    CLINICAL ENDOCRINOLOGY, 2023, 98 (03) : 323 - 331
  • [33] SUPPRESSION OF PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM - DISTINGUISHING PRIMARY FROM SECONDARY ALDOSTERONISM IN HYPERTENSIVE DISEASE
    CONN, JW
    ROVNER, DR
    COHEN, EL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1964, 190 (03): : 213 - &
  • [34] A STUDY OF PRIMARY CARE IN ISCHEMIC-HEART-DISEASE .3.
    KAMIJIMA, G
    SAITO, T
    OISHI, T
    TOKUHIRO, K
    UCHI, T
    MIZOBE, Y
    YASUKAWA, T
    OYA, I
    WATANABE, S
    HIRAMA, T
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1987, 51 (07): : 817 - 818
  • [35] Allicor efficacy in lowering the risk of ischemic heart disease in primary prophylaxis
    Sobenin, IA
    Pryanishnikov, VV
    Kunnova, LM
    Rabinovich, EA
    Orekhov, AN
    TERAPEVTICHESKII ARKHIV, 2005, 77 (12) : 9 - 13
  • [36] C-reactive protein and primary prevention of ischemic heart disease
    Liuzzo, G
    Rizzello, V
    CLINICA CHIMICA ACTA, 2001, 311 (01) : 45 - 48
  • [37] PRIMARY PREVENTION OF ISCHEMIC-HEART-DISEASE - EVALUATION OF COMMUNITY INTERVENTIONS
    WINKELSTEIN, W
    MARMOT, M
    ANNUAL REVIEW OF PUBLIC HEALTH, 1981, 2 : 253 - 276
  • [38] Ischemic heart disease
    Conti, CR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (01) : 1 - 4
  • [39] Ischemic heart disease
    Blanchaert, RH
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1999, 87 (03): : 281 - 283
  • [40] Ischemic heart disease
    Jeffrey S. Schwartz
    Current Treatment Options in Cardiovascular Medicine, 2000, 2 (1) : 27 - 35